ZIB

Hits per page

hits 1 - 2 | 2 hits

Sorting

Electronic Resource

TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease (2000)

Johnston, Janet ; Mudri, Sherri ; Enselman, Rachel ; [et al.]

[s.l.] : Macmillian Magazines Ltd.

Nature 404 (2000), S. 995-999

add to mindlist on the mindlist

Details

ISSN: 1476-4687

Source: Nature Archives 1869 - 2009

Topics: Biology , Chemistry and Pharmacology , Medicine , Natural Sciences in General , Physics

Notes: [Auszug] B cells are important in the development of autoimmune disorders by mechanisms involving disregulated polyclonal B-cell activation, production of pathogenic antibodies, and co-stimulation of autoreactive T cells. zTNF4 (BLyS, BAFF, TALL-1, THANK) is a member of the tumour necrosis factor ...

Type of Medium: Electronic Resource

URL: http://dx.doi.org/10.1038/35010115

Permalink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Paper (German National Licenses)

Fulltext

Electronic Resource

Recombinant Factor XIII Improves Established Experimental Colitis in Rats (2000)

D'argenio, Giuseppe ; Grossman, Angelika ; Cosenza, Vittorio ; [et al.]

Springer

Digestive diseases and sciences 45 (2000), S. 987-997

add to mindlist on the mindlist

Details

ISSN: 1573-2568

Keywords: colitis ; blood coagulation factor XIII ; inflammatory bowel disease

Source: Springer Online Journal Archives 1860-2000

Topics: Medicine

Notes: Abstract Factor XIII (FXIII) is the plasma-borne transglutaminase involved in fibrin clot stabilization and wound healing. FXIII levels in the plasma of patients with inflammatory bowel diseases are lower than normal and there is a significant inverse correlation of FXIII levels with clinical severity. Moreover, uncontrolled studies report beneficial effects of FXIII supplementation in patients resistant to conventional therapies. We investigated the effects of intravenous recombinant FXIII (rFXIII) treatment in experimentally induced rat colitis to verify that FXIII was the active agent in plasma FXIII concentrates and to better understand the potential therapeutic use of this protein. Colitis was induced by instillation of 12% 2,4,6-trinitrobenzenesulfonic acid (TNBS) in 50% ethanol into the colon of male Wistar rats. Rats were treated with 0.65 mg/kg rFXIII or vehicle (intravenously) daily for 10 days. Treatment was started either immediately after TNBS/EtOH instillation (to evaluate effects on developing lesions) or seven days later (to evaluate effects on established lesions). In both cases rats were killed either immediately after the end of treatment (to evaluate immediate effects) or 17 days later (to evaluate long-lasting effects). The effects of rFXIII were compared to positive (5-amino-2-hydroxybenzoic acid) control over a 35-day time course. The severity of lesions was determined by colon weight and macroscopic and histologic scores. Transglutaminase activity was measured in both colon tissue and serum. rFXIII treatment reduced lesion severity significantly not only in developing but also in established lesions. Improvements in healing persisted at least 18 days after treatment was discontinued. Serum and tissue transglutaminase levels were restored by rFXIII treatment. In conclusion, pure rFXIII is as effective as plasma FXIII concentrates in a rat model of experimental colitis. In addition, rFXIII significantly improves the healing of preexisting lesions, a characteristic useful in treatment of human inflammatory bowel diseases.